Non Alcoholic Fatty Liver Disease Influence of Statin Therapy
Recruitment status was Not yet recruiting
- To determine the prevalence of fatty liver in a cohort of patients hospitalized with chest pain in the Cardiology department.
- To assess the effect of statins on the prevalence of fatty liver by a cross sectional survey of patients hospitalized with chest pain.
Non-Alcoholic Fatty Liver Disease (NAFLD)
Procedure: Ultrasound to demonstrate existence of fatty liver
|Study Design:||Primary Purpose: Screening
Time Perspective: Longitudinal
|Study Start Date:||September 2006|
|Estimated Study Completion Date:||September 2009|
Consecutive patients hospitalized with chest pain will be recruited at the cardiology department. Patients with an inflammatory condition, recent infection or history of alcoholism will be excluded. After signing an informed consent each patient will undergo an ultrasound examination for diagnosis of fatty liver. Information regarding BMI, hypertension and use of medications will be collected on each patient. Blood samples for fasting glucose, hemoglobin A1C, lipid profile, ESR, and CRP and liver function tests will be collected from each participant. Prevalence of fatty liver in patients who have been taking statins for 6 months or more statins will be compared to patients who have been taking statins for a lesser period and to those who do have not taken statins using a multivariate regression analysis.
Serum samples will be frozen and kept for future ongoing research.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00375349
|Contact: Michal Mates, MD||0544727635||Mates@013.net|
|Contact: Ornit Cohen Biton, MAemail@example.com|
|Shaare Zedek Medical Center||Not yet recruiting|
|Jerusalem, Israel, 91031|
|Contact: Michal Mates, MD 0544727635 Mates@013.net|
|Principal Investigator: Michal Mates, MD|
|Sub-Investigator: David Meerkin, MD|
|Principal Investigator:||Michal Mates, MD||Shaare Zedek Medical Center|